Consolidated strategy for the analysis of microarray spike-in data by McCall, Matthew N. & Irizarry, Rafael A.
Published online 1 August 2008 Nucleic Acids Research, 2008, Vol. 36, No. 17 e108
doi:10.1093/nar/gkn430
Consolidated strategy for the analysis
of microarray spike-in data
Matthew N. McCall and Rafael A. Irizarry*
Department of Biostatistics, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205, USA
Received April 17, 2008; Revised June 19, 2008; Accepted June 20, 2008
ABSTRACT
As the number of users of microarray technology
continues to grow, so does the importance of plat-
form assessments and comparisons. Spike-in
experiments have been successfully used for inter-
nal technology assessments by microarray manu-
facturers and for comparisons of competing data
analysis approaches. The microarray literature is
saturated with statistical assessments based on
spike-in experiment data. Unfortunately, the statis-
tical assessments vary widely and are applicable
only in specific cases. This has introduced confu-
sion into the debate over best practices with
regards to which platform, protocols and data anal-
ysis tools are best. Furthermore, cross-platform
comparisons have proven difficult because reported
concentrations are not comparable. In this article,
we introduce two new spike-in experiments, present
a novel statistical solution that enables cross-
platform comparisons, and propose a comprehen-
sive procedure for assessments based on spike-in
experiments. The ideas are implemented in a user
friendly Bioconductor package: spkTools. We
demonstrated the utility of our tools by presenting
the first spike-in-based comparison of the three
major platforms–Affymetrix, Agilent and Illumina.
INTRODUCTION
Assessing sensitivity presents a challenge for microarray
technology because one needs experimental designs
in which the correct outcome for a given measurement
is known a priori. Spike-ins provide a way to do this
and are therefore used extensively for assessment pur-
poses (1–8). In fact, spike-in experiments will be integral
to government-led projects that will help determine the
practicality of microarrays in clinical applications. An
example is the External RNA Control Consortium
(ERCC) (9), led by the National Institute for Standards
and Technology (NIST). Creating well-characterized,
tested RNA spike-in controls is the ﬁrst goal of the
ERCC. Proper statistical analysis strategies for the data
generated by these experiments are indispensable.
Unfortunately, the statistical assessments for spike-in
experiments presented in the literature vary widely and
are not generally applicable. For reasons explained in
detailbelow,comparisons acrossplatforms areparticularly
problematic. In this article, we propose a consolidated
strategy that builds on a widely used benchmark methodol-
ogy(10):weassessedspeciﬁcityandsensitivityinawaythat
can be easily related to practical performance. We propose
a solution to the cross-platform problem and demonstrate
its use by analyzing data from spike-in experiments per-
formed by Aﬀymetrix, Agilent and Illumina. The data
were preprocessed with the most commonly used proce-
dures, as described in the next section. We refer to the
processed data (in log2 scale) as expression values.
An important fact that has been overlooked by previous
assessments is that microarray performance largely
depends on concentration levels (11). Assessments based
on experiments for which spike-in concentrations lead to
unusually high expression measurements have resulted in
misleading conclusions (12). For this reason, it is essential
that the distribution of observed expression for the spike-in
transcripts reﬂects the distributions seen in typical experi-
ments.Figure1showsthetypicaldistribution ofexpression
values for the background RNA for the three studied data
sets. The tick marks on the x-axis represent the average
expression at each reported spike-in level. This ﬁgure illus-
tratesthatthe spike-in transcripts resulted in higher expres-
sionmeasurements,onaverage,thanthebackgroundRNA
transcripts. Furthermore, we see that, relative to their
respective background RNA distributions, the Agilent
and Illumina spike-ins have higher observed expression
than those in the Aﬀymetrix experiment. Previous work
(11) suggests that comparing platform performance with-
out correcting for this leaves Aﬀymetrix at a disadvantage.
For spike-in experiments to be useful in a cross-study
assessment, we need to understand how the reported nom-
inal concentrations relate across data sets. The reported
concentrations attempt to quantify the amount of spike-
in RNA in a sample relative to the total amount of RNA.
However, in our experience, the reported values are
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One reason is that two approaches have been used: (i)
adding prelabeled spike-ins to the target solution just
before hybridization and (ii) adding spike-ins to the total
RNA at the beginning of ampliﬁcation. We prefer the
second approach because it better imitates a real experi-
ment (13). Speciﬁcally, itreproduces the technical variation
due to cDNA synthesis, fragmentation, labeling and
hybridization. However, the Aﬀymetrix and Illumina
data presented in this article are from experiments that
followed the ﬁrst approach, while the Agilent experiment
followed the second approach. A molarity calculation is
easy to perform in the ﬁrst approach but diﬃcult in the
second because the only true known values in the experi-
ment are the mass of the spike-in and the mass of total
RNA. For this reason, Agilent reports nominal values in
diﬀerent units (relative concentration) than Aﬀymetrix and
Illumina[picomolar(pM)].However,evenwhenpicomolar
concentrations are reported we ﬁnd that nominal concen-
trations do not map well across experiments (Table 1). We
hope that the ERCC will solve this problem by standardiz-
ing protocols. Here, we propose a data-driven solution that
permits cross-platform comparison with existing data sets.
MATERIALS AND METHODS
Experimental protocols
The platforms used were Aﬀymetrix’s HGU133A
GeneChip, Agilent’s 4x44K Whole Human Genome
Oligo Microarray and Illumina’s Human-6 v2 Beadchip.
The experiments for each platform were performed by the
respective manufacturer. Each manufacturer followed
diﬀerent experimental procedures (Table 2). The raw
data were preprocessed with the default procedures:
Aﬀymetrix was preprocessed using RMA (14); Agilent
used background subtraction and normalized to the 75th
percentile; Illumina used local background subtraction
and quantile normalization (15).
Relatingnominal concentrations across datasets
Our solution to the problem of mapping was to replace
each nominal concentration with the average log expres-
sion across arrays (ALE) for genes spiked in at that con-
centration. This approach assures that performance
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Figure 1. Empirical densities. These plots depict the empirical density of the average (across arrays) expression values for the background RNA. The
tick marks on the x-axis show the average expression at each nominal concentration. The dotted lines represent the cut points for low, medium and
high ALE values (deﬁned in text).
Table 1. Nominal concentration to ALE mapping
Reported nominal
concentration
Average
expression value
Proportion of
genes below
ALE
strata
SD
Aﬀymetrix (pM)
0.125 5.1 0.35 Low 0.87
0.250 5.2 0.38 Low 0.90
0.500 5.3 0.40 Low 0.74
1.000 5.7 0.48 Low 0.72
2.000 6.4 0.62 Med 0.82
4.000 7.1 0.73 Med 0.79
8.000 7.8 0.82 Med 0.68
16.000 8.4 0.89 Med 0.67
32.000 9.3 0.94 Med 0.79
64.000 10.2 0.97 Med 0.72
128.000 11.2 0.99 Med 0.54
256.000 12.0 0.99 High 0.49
512.000 12.6 1.00 High 0.51
Agilent (relative concentration)
Reported nominal concentration
0.20 4.6 0.34 Low 1.35
2.00 4.8 0.36 Low 1.40
20.00 6.3 0.49 Low 0.63
200.00 9.1 0.73 Med 0.47
666.67 10.9 0.86 Med 0.36
2000.00 12.5 0.94 Med 0.3
6666.67 14.2 0.97 Med 0.21
20000.00 15.6 0.99 Med 0.16
66666.67 17.1 1.00 High 0.31
200000.00 18.0 1.00 High 0.25
Illumina (pM)
Reported nominal concentration
0.01 2.9 0.38 Low 0.39
0.03 3.0 0.49 Low 0.46
0.10 3.9 0.68 Med 0.83
0.30 5.4 0.76 Med 1.51
1.00 7.5 0.85 Med 1.26
3.00 9.5 0.94 Med 1.05
10.00 11.4 0.98 Med 1.01
30.00 12.8 1.00 High 0.81
100.00 14.1 1.00 High 0.65
300.00 14.8 1.00 High 0.34
1000.00 15.0 1.00 High 0.26
This table contains summary measures speciﬁc to each nominal spike-in
level. The ﬁrst column shows the nominal concentrations as originally
reported. The secondcolumn showsthe averageofallobserved expression
values associated with the row’s nominal concentration. The third column
shows the proportion of background RNA with expression values less
than the average expression value. The fourth column shows the ALE
strata (deﬁned in text) associated with the row’s nominal concentration.
Finally, the ﬁfth column shows the SD of all observed expression values
associated with the row’s nominal concentration.
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sion measurements that are deﬁned consistently across
platforms: low, medium and high ALE values correspond
to low, medium and high observed expression values,
respectively (Table 1).
Accuracy assessment
With the ALE values in place, we were ready to adapt some
of the existing statistical assessments to cross-platform
comparisons. We started with a basic assessment of
accuracy: the signal detection slope (10). Microarrays are
designed to measure the abundance of sample RNA. In
principle, we expect a doubling of nominal concentration
to result in a doubling of observed intensity. In other
words, on the log2 scale, the slope from the regression of
expression on nominal concentration can be interpreted as
the expected observed diﬀerence when the true diﬀerence is
a fold change of 2. Thus, an optimal result is a slope of one,
and values higher and lower than one are associated with
over and under estimation, respectively (Figure 2).
ALE strata
It has been noted that at very high and very low concen-
trations one typically observes lower slopes compared to
those seen at medium concentrations (11). To address this,
we consider the signal detection slopes for genes spiked-in
at low, medium and high ALE values (Figure 2). We
implemented a data-driven approach to selecting these
two cut-oﬀs.
We deﬁned f to be the function that maps nominal log
concentration x to expected observed concentration f(x).
Using a cubic spline, ﬁtted to the observed data, we
obtained a parametric representation of f. We then
looked for concentrations for which clear changes in sen-
sitivity occurred, i.e. values of x with large slope changes.
Note that large changes in slope result in local maxima in
the absolute value of the second derivative of f. For each
platform, the absolute value of the second derivative f 00
showed two clear local maxima (Supplementary Figure 1).
For each platform, we mapped each concentration x to its
corresponding empirical percentile (x) and plotted jf00ðxÞj
against (x) (Supplementary Figure 2). The percentiles
that maximized the slope change were similar across plat-
forms. The modes for the average curve were 0.615 and
0.993. Therefore, for the purpose of this comparison, we
assigned as low, ALE values less than the 60th percentile
of the distribution of background RNA. Similarly, we
deﬁned as high ALE values above the 99th percentile.
The remaining ALE values, between the 60th and 99th
percentile, were denoted as medium. Our choice of cut-
points was further motivated by observing that for the
Aﬀymetrix data the 60th percentile provided a good cut-
oﬀ for distinguishing genes called present from genes
called absent (Supplementary Figure 3).
Precision assessments
To complete our comparison, we needed to assess speciﬁ-
city. Because the majority of microarray studies rely on
Table 2. Description of data sets
Aﬀymetrix Agilent Illumina
Background RNA HeLa complex cRNA Human Osteosarcoma (MG-63)
purchased from Ambion (Cat. # 7868)
Human Liver purchased
from Ambion (Cat. # 7960)
Spike-in production 30 cDNA clones isolated
from a lymphoblast cell line,
eight artiﬁcially engineered,
four eukaryotic controls from
the polyA spike control kit
In vitro synthesized,
polyadenylated transcripts
derived from the Adenovirus
E1A gene
In vitro transcription of cloned
bacterial and viral genes
Background correction RMA Background subtraction and spatial-detrending Local background subtraction
Normalization RMA Normalized to the 75th
percentile on each microarray
Quantile normalization
This table gives a brief comparison of the three data sets used in this analysis.
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Figure 2. Observed versus nominal values. For each of the three platforms, expression values are plotted against the log (base 2) of the reported
nominal concentration. The regression slope obtained utilizing all the data and the regression slopes obtain within each ALE value strata are shown.
The slope of each line is reported in the legend. The vertical lines divide the ALE strata.
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ones, we focused on the precision of the basic unit of
relative expression: log-ratios. We adapted the precision
assessment of Cope et al. (10) that focused on the vari-
ability of log-ratios generated by comparisons expected to
produce log-ratios of 0. Our set of comparisons was cre-
ated by making all possible comparisons between spiked-
in transcripts across arrays in which they had the same
nominal concentration and from all possible comparisons
within the background RNA. We referred to this group of
comparisons as the Null set. The SD of these log-ratios
served as a basic assessment of precision and has a useful
interpretation: it is the expected range of observed log-
ratios for genes that are not diﬀerentially expressed.
Table 3 and Figure 3 show results for the three platforms.
Because speciﬁcity varies with nominal concentration
(11), we stratiﬁed these comparisons into low, medium
and high ALE values. In Figure 3, many outliers were
observed on each platform. This was expected given the
documented problem of cross-hybridization. Because a
platform with larger SD and small outliers might be pre-
ferable to the one with a smaller SD but large outliers, we
included the 99.5th percentile of the null distribution as a
second summary assessment of speciﬁcity. Note that in a
typical experiment close to 0.5% of null genes are expected
to exceed this value, which translates to approximately
100 genes on whole-genome arrays. Figure 3 also includes
comparisons of spike-ins expected to yield a certain fold
change. These serve to further demonstrate the variability
of relative expression across ALE strata. They also serve
as a rough illustration of the accuracy of log-ratios for
each ALE strata and each platform.
Performance assessments
Precision and accuracy assessments on their own may not
be of much practical use. However, the summary statistics
described earlier (Table 3) can be easily combined to
answer any practical question, as long as it can be posed
in a statistical context. We focus on two summaries related
to the common problem of detecting diﬀerentially
expressed genes. Note that we purposely developed
summaries that do not directly penalize for a lack of
accuracy and precision as long as the real diﬀerences are
detected. However, as expected, detection ability was
highly dependent on accuracy and precision.
For the ﬁrst example, we computed the chance that,
when comparing two samples, a gene with true log fold
change =1 will appear in a list of the top 100 genes
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Figure 3. Log-ratio distributions. These plots depict the distribution of observed log ratios for various nominal fold changes. In each case, the log
ratios are stratiﬁed by the ALE values into which the two nominal concentrations fall. For example, HL means that one fell in the high stratum and
one fell in the medium stratum. The null distributions’ log-ratios are divided into background RNA (Bg-Null) and spike-ins at the same nominal
concentration (S-Null), for each bin. The dotted horizontal lines represent the expected or nominal log-ratios: zero for the null distribution and  for
the other comparisons ( ¼ log2 4 for Aﬀymetrix and  ¼ log2 3 for Agilent and Illumina).
Table 3. Assessment results
Accuracy Precision Performance
Platform Slope (SD) SD 99.5% SNR POT GNN
Low
Aﬀymetrix (RMA) 0.20 (0.31) 0.10 0.36 2.00 0.30 13
Aﬀymetrix (MAS5) 0.58 (0.73) 0.64 3.54 0.91 0.00 581
Agilent 0.26 (0.90) 0.40 2.74 0.65 0.00 246
Illumina 0.11 (0.39) 0.35 1.18 0.31 0.00 506
Medium
Aﬀymetrix (RMA) 0.79 (0.35) 0.09 0.40 8.78 0.87 19
Aﬀymetrix (MAS5) 0.80 (0.38) 0.18 0.95 4.44 0.35 24
Agilent 0.99 (0.17) 0.11 0.86 9.00 0.78 20
Illumina 1.15 (0.37) 0.25 1.48 4.60 0.19 25
High
Aﬀymetrix (RMA) 0.57 (0.15) 0.06 0.22 9.50 0.99 10
Aﬀymetrix (MAS5) 0.48 (0.19) 0.13 0.42 3.69 0.62 10
Agilent 0.61 (0.29) 0.10 0.38 6.10 0.79 10
Illumina 0.42 (0.32) 0.15 0.62 2.80 0.27 15
For each of the ALE strata, we report summary assessments for accur-
acy, precision and overall performance. The ﬁrst column shows the
signal detection slope, which can be interpreted as the expected
observed diﬀerence when the true diﬀerence is a fold change of 2. In
parenthesis is the SD of the log-ratios associated with nonzero nominal
log-ratios. The second column shows the standard deviation of null log-
ratios. The SD can be interpreted as the expected range of observed
log-ratios for genes that are not diﬀerentially expressed. The third
column shows the 99.5th percentile of the null distribution. It can be
interpreted as the expected minimum value that the top 100 nondiﬀer-
entially expressed genes will reach. The fourth column shows the ratio
of the values in column 1 and column 2. It is a rough measure of signal
to noise ratio. The ﬁfth column shows the probability that, when com-
paring two samples, a gene with a true log-fold change of 2 will appear
in a list of the 100 genes with the highest log-ratios. The sixth column
shows the size of gene list necessary to obtain 10 true positives when
one considers a list of genes with the highest fold change.
e108 Nucleic Acids Research, 2008, Vol. 36, No. 17 PAGE4 OF 7(highest log-ratios). We refer to this quantity as the prob-
ability of being at the top (POT) and recommend comput-
ing it separately in each ALE strata. Speciﬁcally, we
assume that the log-ratios in each ALE strata follow a
normal distribution with mean and variance estimated
from the data (accuracy slope and SD in Table 3) and
compute the probability that a random variable from
that distribution exceeds the 99.5th percentile of the null
distribution.
As a second example, we computed the expected size of
a gene list one would have to consider to ﬁnd n genes that
have a true log fold change . To perform this calculation,
we assumed m1 genes were diﬀerentially expressed and m0
were not. Note that m1 þ m0 is the number of genes on the
array. Furthermore, we assumed that the true log-ratios in
each ALE strata followed a normal distribution with
mean and variance estimated from the data (accuracy
slope and SD in Table 3). The empirical distribution was
used for the null genes. With these assumptions in place,
we computed the gene list size for n=10, m1=100 and
m0=10000, we calculate the gene list size, N, required to
obtain n=10 true fold changes (Table 3). We refer to this
quantity as the gene-list needed to detect n true-positives
(GNN). Again, we recommend computing it separately in
each ALE strata.
Imbalance measure
Those interested in taking advantage of our methodology
should know that an important requirement is a spike-in
experimental design that does not confound nominal con-
centrations and genes. A large source of variability in
microarray data is the probe-eﬀect (16) and these vary
across platforms. We ﬁtted an analysis of variance
(ANOVA) model to describe the probe eﬀect for each
platform (Table 4). Note that if nominal concentrations
are confounded with genes, it becomes impossible to
separate diﬀerences due to signal detection from dif-
ferences in probe aﬃnities. Many of the previously pub-
lished spike-in experiments suﬀer from this confounding
eﬀect. To quantify design imbalance, we used the follow-
ing measure of imbalance developed by Wu (17):
IB ¼
X p
i¼1
 i
X ri
ui
 X T
t¼1
n2
tðuiÞ 
1
T
n2ðuiÞ
 
1
where i denotes each covariate,  i an optional weight asso-
ciated with each covariate, ui are the possible levels for
covariate i, t represents the treatment levels, ntðuiÞ is the
number of units with its i-th covariate at level ui receiving
treatment t, and nðuiÞ is the total number of units with its
i-th covariate at level ui (17). In our case, the two covari-
ates are probe and array, and the treatment is nominal
concentration. Since imbalance is deﬁned as a weighted
sum of the imbalance due to each covariate, we chose to
report the probe and array imbalance separately to give a
better understanding of the source of the imbalance in
each design. In order to not penalize large designs, we
divided the probe imbalance by the number of probes
and the array imbalance by the number of arrays. These
results are included in Table 4.
We have developed a software package that permits
quick and easy creation of plots and tables such as those
presented here. The software is freely available as the
spkTools package from the Bioconductor Project (18).
This package deﬁnes a new S4 class that extends the
ExpressionSet class (18) to include a matrix of nom-
inal concentrations; this new class is called SpikeIn
ExpressionSet. The functions implemented in this
package take an object of this type as their input and
automatically produce the tables and plots presented in
this paper. Of particular interest is a function named
spkAll, which is a wrapper function for all the
functions contained in this package. When run on a
SpikeInExpressionSet object, it produces the full
complement of tables and plots shown in this article and
saves them with easily recognizable ﬁle names. Although
this package was designed with the intent of producing the
full array of results for each experiment, the functions can
also be applied separately with a few exceptions where the
output of one function is required as the input of another.
Further details and examples outlining the use of these
functions can be found in the help ﬁles accompanying
the package.
RESULTS
The ANOVA analysis (Table 4) revealed that all platforms
have similar sized probe eﬀects. This underscores the
importance of balancing genes and concentration levels.
The Agilent experiment had a small imbalance (Table 4).
This was because Agilent used one less concentration
mixture than the number of spike-in probes. The
Illumina array had a very large array imbalance because
array and concentration were completely confounded.
Table 4. ANOVA results
Platform Aﬀymetrix
(RMA)
Aﬀymetrix
(MAS5)
Agilent Illumina
Concentration eﬀect 2.48 2.77 4.53 2.19
Probe eﬀect 0.54 0.55 0.44 0.38
Array eﬀect 0.17 0.17 0.19 NA
Measurement error 0.47 0.72 0.69 0.54
Probe imbalance 0 0 3.60 0
Array imbalance 0 0 0 1059.67
To understand the variability contributed by diﬀerences in nominal
concentrations, probe eﬀect and array, we ﬁtted a three-way ANOVA
model containing only main eﬀects to the expression values from the
spike-in transcripts. The estimated SD of each eﬀect is shown in the
ﬁrst three rows. The fourth row shows the SD of the error term.
Finally, a measure of the amount of confounding between nominal
concentration and the other two eﬀects is included in rows ﬁve and
six. We use the measure presented by Wu (17). An optimal design,
such as a Latin Square, will have a measure of 0 for each imbalance.
The more confounding the larger these values. Note, the large imbal-
ance due to array in the Illumina design. In this experiment array and
nominal concentration were completely confounded. However, because
the array eﬀect is small (the arrays are normalized) this was not as
much of a problem. In the Agilent experiment, there is a small
amount of confounding between probe and concentration because a
Latin Square design was used with a single concentration/gene combi-
nation missing.
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expected the array eﬀect for Illumina to be small, as
with Aﬀymetrix and Agilent. This type of confounding
is therefore less problematic.
Figure 2 demonstrated that Agilent performed best with
regardtoaccuracyinallconcentrationbins.WhileIllumina
performed better than Aﬀymetrix in the medium concen-
trations, Aﬀymetrix performed better in the low and high
concentrations. Aﬀymetrix was most consistent across all
bins. If we had looked at only the overall slope, Illumina
would have appeared to perform best because fold changes
are overestimated in the medium concentrations. Figure 2
also shows the changing relationship between expression
and nominal concentration. For all three platforms, the
slope is small at low nominal concentrations, larger at
highconcentrations,andlargestatmediumconcentrations.
However, the diﬀerence between these slopes and the nom-
inal concentrations at which the shift between bins occurs
varies across platforms. It is this fact that illustrates why it
is crucial to view nominal concentration and expression as
platform dependent measures.
Figure 3 highlights two important ﬁndings: (i) precision
depends strongly on concentration with higher variability
observed forlow concentrations, (ii) Aﬀymetrix, which had
the worst accuracy, has the best precision, especially for
low concentrations where the diﬀerence was substantial.
In terms of the POT and GNN assessment, Aﬀymetrix
outperforms Agilent which outperforms Illumina: the gene
list size in the low/medium/high strata for Aﬀymetrix were
37/34/25, for Agilent they were 682/38/26 and for Illumina
they were 1489/60/46 (Table 3). To provide a graphical
version of this summary, we included boxplots of observed
log-ratios for comparison with nonzero nominal log-fold
changes >0 (Figure 3). Due to the diﬀerent designs,
using the same expected log-fold change, , for all plat-
forms was not possible. We used the closest possible
values instead: log2ð4Þ for Aﬀymetrix and log2ð3Þ for
Agilent and Illumina. Log ratio (M) versus average inten-
sity (A) plots also depict both accuracy and precision and
are included as Supplementary Figure 4.
DISCUSSION
We have described a general assessment procedure for
microarraydatabasedonspike-inexperimentsanddemon-
strated how the procedure can be used to compare across
diﬀerent experiments and microarray platforms. A novel
aspect of the approach is that we independently assess per-
formance at low, medium, and high concentrations using
ALE values: an empirically constructed mapping between
nominalconcentration andobservedexpression.Thismap-
ping is important because nominal concentrations can not
be interpreted in the same way in all experiments. In our
approach, measurements are interpreted relative to the dis-
tribution of background RNA expression.
Our results demonstrate that while Agilent and Illumina
had better overall accuracy, Aﬀymetrix has better preci-
sion. In the medium and high strata, Aﬀymetrix and
Agilent performed similarly, and better than Illumina,
according to the POT and GNN measures. In the low
strata, Aﬀymetrix greatly outperformed Agilent and
Illumina. Aﬀymetrix’s advantage was due to the
smaller number of outliers (Table 3 and Supplementary
Figure 1). Note that to keep the article focused, we con-
sidered a basic analysis approach based on fold change.
However, the spkTools package can be used for more
elaborate platform comparisons. For example, to help
reduce outliers, we ﬁltered genes called absent or unde-
tected by the manufacturer’s software. Because various
noisy comparisons are no longer considered, this approach
improves speciﬁcity in the low strata. However, sensitivity
is made worse because true diﬀerences are accidentally
ﬁltered away (Supplementary Table 1). Problems with
these detection calls have been documented (19).
As we previously described the 60th and 99th percentiles
provided the best cut-points for this analysis; however,
that need not be the case in future analyses. For this
reason, the spkTools package permits the user to
choose any two percentiles to use as the cut-points. We
recommend that the optimal cut-points for a future data
set be determined in a manner similar to what we
described.
It is important to note that the microarray products
compared here are of diﬀerent generations, with
Aﬀymetrix’s the oldest and Agilent’s the newest. Also,
the spike-in targets and background RNA vary between
platforms (Table 2). Finally, diﬀerent preprocessing algo-
rithms will result in diﬀerences in performance (16). To
illustrate this, we ran Aﬀymetrix data processed with the
manufacturers default MAS 5.0 through our assessment
(Table 3 and Supplementary Figure 6). An interesting
ﬁnding was that with MAS 5.0, instead of RMA,
Aﬀymetrix no longer had an advantage in the low
strata. We expect results for Agilent and Illumina to
improve with the development of novel preprocessing
algorithms for these technologies by the scientiﬁc commu-
nity. Because we expect a large increase in spike-in experi-
ments and preprocessing algorithms, we developed the
spkTools package to permit quick and easy creation
of plots such as those presented here.
Spike-in experiments have been criticized for producing
artiﬁcial data with little resemblance to real data produced
by a typical experiment. A particular limitation of the data
shownhereistheuseoftechnicalreplicates:thedatafailsto
incorporate the biological variation present in most experi-
ments. However, acceptable sensitivity and speciﬁcity mea-
sures, determined by spike-in experiments such as those
presented here, are a minimal requirement for amicroarray
platform. A technology not performing well in our assess-
ment will not perform well in the more complicated setting
of real experiments. A strength of our spike-in data is that
they permit a focused assessment based on the most basic
attributes of this technology. Furthermore, we expect
vastly improved spike-in experiments, e.g. using biological
replicates, to emerge in large numbers once the ERCC
makes it ﬁrst formal recommendation. We have therefore
developed a general tool that can be readily applied to data
from these experiments. Furthermore, the strategy we
described and used successfully to compare the three
main microarray platforms using Latin-Square spike-in
e108 Nucleic Acids Research, 2008, Vol. 36, No. 17 PAGE6 OF 7experiments for the ﬁrst time, can serve as a blueprint for
future methods and analyses.
SUPPLEMENTARY DATA
Supplementary data are available at NAR Online.
Raw data and annotation ﬁles are available from http://
rafalab.org.
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